@prefix this: <http://bio2rdf.org/drugbank_resource:DB00213_DB01030_nanopub.RADkrt2-9T3VSKgFdlq29gfEeR5qY8QFTT8WHh6J735m4> .
@prefix sub: <http://bio2rdf.org/drugbank_resource:DB00213_DB01030_nanopub.RADkrt2-9T3VSKgFdlq29gfEeR5qY8QFTT8WHh6J735m4#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix pav: <http://purl.org/pav/> .
@prefix orcid: <http://orcid.org/> .
@prefix codebase: <https://github.com/tkuhn/bio2rdf2nanopub> .
@prefix version: <https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349> .
@prefix instance: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB> .
@prefix process: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix has-source: <http://semanticscience.org/resource/SIO_000253> .
@prefix d: <http://bio2rdf.org/drugbank:> .
@prefix dv: <http://bio2rdf.org/drugbank_vocabulary:> .
@prefix dr: <http://bio2rdf.org/drugbank_resource:> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:publicationInfo;
    a np:Nanopublication .
}

sub:assertion {
  d:DB00213 dv:ddi-interactor-in dr:DB00213_DB01030 .
  
  d:DB01030 dv:ddi-interactor-in dr:DB00213_DB01030 .
  
  dr:DB00213_DB01030 dct:identifier "drugbank_resource:DB00213_DB01030";
    dct:title "DDI between Pantoprazole and Topotecan - The BCRP/ABCG2 inhibitor, Pantaprazole, may increase the bioavailability and serum concentration of oral Topotecan. Monitor for change in the therapeutic and adverse effects of Topotecan if Pantaprazole is initiated, discontinued or dose changed."@en;
    a dv:Drug-Drug-Interaction;
    rdfs:label "DDI between Pantoprazole and Topotecan - The BCRP/ABCG2 inhibitor, Pantaprazole, may increase the bioavailability and serum concentration of oral Topotecan. Monitor for change in the therapeutic and adverse effects of Topotecan if Pantaprazole is initiated, discontinued or dose changed.  [drugbank_resource:DB00213_DB01030]"@en .
}

sub:provenance {
  sub:assertion has-source: dr:bio2rdf.dataset.drugbank.R3 .
}

sub:publicationInfo {
  sub:signature.MCwCFDznklbVNqni npx:hasPublicKey "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";
    npx:hasSignature "MCwCFDznklbVNqnivQI/QuBUrE0oliXUAhRtxP7DciTb6en3/t7S7Z/2homV0g==";
    npx:signedBy instance: .
  
  this: dct:created "2018-03-30T11:12:48.166+02:00"^^xsd:dateTime;
    dct:license <https://creativecommons.org/licenses/by-nc/4.0/>;
    npx:hasSignatureElement sub:signature.MCwCFDznklbVNqni;
    prov:wasGeneratedBy process: .
  
  instance: prov:specializationOf codebase:;
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
  
  process: dct:identifier "3c184e6c-ceb8-4275-a679-71dfbdac2a11";
    prov:used version:;
    prov:wasAssociatedWith instance:;
    prov:wasStartedBy orcid:0000-0002-1267-0234 .
  
  version: dct:isVersionOf codebase:;
    pav:version "eda7951a5f6c622c5d2132f50c3093138484a349";
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
}